Saturday, 12 September 2026

The week in review

Neutral is the model’s latest close-of-day regime read, its first neutral print and a flip from risk-off, with mixed breadth and a calm VIX of 15.84. Only 41.8% of scanned US stocks (409 of 978) stood above their 50-day average. SPY closed at 764.14, above its 200-EMA of 718.80; the distance was +6.3%.

Rate pressure increased. The 10 September FRED readings put the 10Y Treasury yield at 4.95%, week over week +17bps, and the 2Y at 4.56%, week over week +19bps. The real 10Y rate reached 2.59%, week over week +16bps. By 11 September, 10Y breakeven inflation was 2.36%, week over week +1bps.

Credit showed less movement: the 10 September high-yield spread was 2.70%, week over week +2bps. Higher real rates and mixed participation best explain the neutral read. These observations do not establish which event caused the week’s equity moves.

Themes in motion

The model describes oil, energy and geopolitics, crypto exchanges and financials, freight and logistics, cyclical industrials, and precision biotech and therapeutics as narratives that are maturing.

The AI datacenter infrastructure narrative reads as saturated, as are mega-cap AI platforms, semi foundry and equipment, GPU cloud and neoclouds, and medtech and diagnostics.

Company evidence remains more specific than those classifications. Halozyme’s August earnings release raised guidance, while Iovance’s August release put guidance under review for an upward revision. Those dated disclosures support company-level operating cases; they do not establish a broader healthcare trend.

Under the lens

The highest-conviction theses center on merger outcomes, while selected high-conviction cases depend on healthcare execution and federal detention contracts.

The merger grouping means contractual and regulatory milestones determine the case. Apogee is already resolved; the other cited transactions still require evidence of completion.

• Apogee Therapeutics (APGE) remains in the highest conviction tier, but its published thesis records a completed outcome: the AbbVie merger became effective 3 September, and Nasdaq suspended the stock 4 September. That evidence settles the acquisition thesis; it supplies no continuing standalone equity case.

• AtaiBeckley (ATAI) is in the highest conviction tier on antitrust progress. The thesis records German clearance on 30 July, no further UK CMA questions on 21 August, and HSR expiry on 28 August. The Australian waiting-period reference is incomplete, so it cannot establish that milestone. A closing announcement would settle completion; a blocking regulatory decision or termination would invalidate that case.

• Distribution Solutions Group (DSGR) is in the highest conviction tier because LKCM Headwater’s 16 July cash acquisition agreement makes completion the central question. Closing on the agreed terms would confirm the thesis; termination or reduced consideration would break it.

• Atkore (ATKR) is rated high conviction around the pending HSR milestone. Notifications were filed 14 August, with expiry expected 14 September. The thesis reports no definitive proxy in EDGAR as of 6 September. Regulatory progress and a definitive meeting timetable would strengthen the completion case; a blocking decision or termination would invalidate it.

• Bowman Consulting Group (BWMN) is rated high conviction on its announced cash acquisition. The 13 September go-shop deadline addresses the solicitation stage. Closing would settle the thesis; transaction termination would invalidate it.

The healthcare grouping separates reported operating progress from scheduled opportunities to update it.

• Halozyme Therapeutics (HALO) is rated high conviction on royalty-led earnings growth. Its 6 August results exceeded the revenue consensus and raised annual earnings guidance. Subsequent royalty growth and maintained or higher guidance would confirm the case; a reversal of the earnings uplift would undermine it.

• Iovance Biotherapeutics (IOVA) is rated high conviction on Amtagvi’s commercial ramp. Following the 6 August results, management put annual revenue guidance under review for an upward revision. Publication of higher guidance would confirm that specific claim; unchanged or lower guidance would invalidate the promised upward revision.

• LifeStance Health Group (LFST) is rated high conviction on a margin-improvement thesis, but the latest company update is its 1 September announcement of conference appearances. Those appearances provide an opportunity for evidence. Reported margin improvement would support the case; reported deterioration would contradict it. Attendance alone settles neither outcome.

The detention grouping concerns different revenue mechanisms: property sales with continued operations at CoreCivic, and signed operating contracts at GEO.

• CoreCivic (CXW) is rated high conviction because the thesis describes DHS buying detention properties while CoreCivic continues operating them. Completed sales and confirmed operating arrangements would substantiate that structure; cancellation or loss of the operating role would break it.

• The GEO Group (GEO) is rated high conviction on ICE contracts effective 9 July and 1 August, alongside increased earnings guidance. Revenue delivery under those contracts would confirm the conversion from capacity narrative to operations; cancellations or guidance reductions tied to execution would undermine it.

The week ahead

Next week’s calendar tests Atkore’s regulatory progress, healthcare clinical and policy evidence, and LifeStance’s operating narrative.

• 13 September — Bowman Consulting: The scheduled go-shop expiry precedes the trading week. Confirmed expiry would establish completion of that solicitation stage; an extension would invalidate the scheduled milestone. Neither outcome establishes merger completion.

• 14 September — Atkore: The initial HSR waiting period is expected to expire. Confirmed expiry without an extension or further request would resolve that initial gate; a delay or challenge would break the expected timetable.

• 14 September — Cullinan Therapeutics (CGEM): REZILIENT3 interim results are scheduled for presentation. Reported efficacy and safety will provide evidence for the therapeutic case. A favorable interpretation requires supportive clinical findings; weak efficacy or material safety problems would contradict it. The calendar contains no results.

• 14 September — COMPASS Pathways (CMPS): The FDA public hearing addresses therapeutic use of psychedelic products in supervised, supportive settings. The hearing record may clarify regulatory requirements. An inference of an easier development path would require explicit supporting statements; additional restrictive requirements would contradict it. The hearing itself does not resolve product approval.

• 14 September and 15 September — LifeStance: The announced CFO appearance at Jefferies and CEO appearance at Morgan Stanley may update the margin thesis. New operating disclosures showing improvement would support it; deterioration would contradict it. Presentations without new operating evidence would leave the thesis unresolved.